Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by TD Asset Management Inc

TD Asset Management Inc increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.1% in the 2nd quarter, Holdings Channel.com reports. The firm owned 413,150 shares of the medical instruments supplier’s stock after acquiring an additional 23,909 shares during the quarter. TD Asset Management Inc’s holdings in Becton, Dickinson and Company were worth $96,557,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of BDX. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at approximately $27,000. OLD Point Trust & Financial Services N A acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth $29,000. Scarborough Advisors LLC acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth $32,000. Rise Advisors LLC purchased a new stake in Becton, Dickinson and Company in the first quarter valued at $38,000. Finally, ICA Group Wealth Management LLC acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $42,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.3 %

Becton, Dickinson and Company stock opened at $233.15 on Friday. The firm has a market capitalization of $67.38 billion, a P/E ratio of 51.35, a P/E/G ratio of 1.98 and a beta of 0.42. The stock’s fifty day simple moving average is $234.09 and its 200-day simple moving average is $236.02. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $272.14. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.96 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Evercore ISI reduced their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target on the stock. Citigroup lowered their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Raymond James lowered their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.